Efocipegtrutide vs HRS-4729

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline

Efocipegtrutide

Developed by Hanmi Pharmaceutical

Phase 1 in Obesitypeptide
Weak signal

NCT03374241 · Phase 1 · completed

The study was randomized, blinded and placebo-controlled, a solid safety-study design, but its only primary measure was a count of adverse events rather than a clinical or weight-related efficacy outcome, and no statistical test was applied to those counts. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants With Adverse Events (1 month): Number of Participants With Adverse Events (1 month): Cohort 1 Active 3 Participants | Cohort 2 Active 2 Participants | Cohort 3 Active 3 Participants | Cohort 4 Active 7 Participants | Cohort 5 Active 4 Participants | Placebo 7 Participants (not_applicable)

Result source: NCT03374241

HRS-4729

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 2 in Obesitypeptide
Weak signal

NCT06762600 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: March 2027 · NCT07690826 (registry estimate)

Reported efficacy

Adverse events (AEs) (Screening period up to day 43.): In the multiple-dose portion at Week 12, participants receiving multiple doses of 12 mg HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo. HRS-4729 demonstrated linear pharmacokinetics with a half-life of approximately 4 to 5 days, supporting once-weekly dosing, and safety and tolerability consistent with GLP-1-based treatments. (not_applicable)

Result source: NCT06762600

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEfocipegtrutideHRS-4729
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

Efocipegtrutide
—Not reported
HRS-4729
—Not reported

Weight loss of 5% or more

Efocipegtrutide
—Not reported
HRS-4729
—Not reported

Weight loss of 10% or more

Efocipegtrutide
—Not reported
HRS-4729
—Not reported

Waist circumference, change (cm)

Efocipegtrutide
—Not reported
HRS-4729
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-4729: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Efocipegtrutide: 3 of 4 rows · HRS-4729: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEfocipegtrutide
Dropout rate
—Cohort 1 Activea
NCT03374241 · Phase 1
show 9 more results
—Cohort 2 Active
NCT03374241 · Phase 1
—Cohort 3 Active
NCT03374241 · Phase 1
—Cohort 4 Active
NCT03374241 · Phase 1
—Cohort 5 Active
NCT03374241 · Phase 1
11.1%0.08 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
16.7%0.04 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.02 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.01 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—Cohort 1 Activea
NCT03374241 · Phase 1
show 9 more results
—Cohort 2 Active
NCT03374241 · Phase 1
—Cohort 3 Active
NCT03374241 · Phase 1
—Cohort 4 Active
NCT03374241 · Phase 1
—Cohort 5 Active
NCT03374241 · Phase 1
—0.08 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
—0.06 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
—0.04 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
—0.02 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
—0.01 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
Serious AEs
0%Cohort 1 Activea
NCT03374241 · Phase 1
show 9 more results
0%Cohort 2 Active
NCT03374241 · Phase 1
0%Cohort 3 Active
NCT03374241 · Phase 1
0%Cohort 4 Active
NCT03374241 · Phase 1
0%Cohort 5 Active
NCT03374241 · Phase 1
0%0.08 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.04 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.02 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
0%0.01 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
general disorders and administration 33.3% (placebo 40%)
infections and infestations 16.7% (placebo 0%)
musculoskeletal and connective tissue 16.7% (placebo 0%)
NCT03374241 · Phase 1
show 9 more results
blood and lymphatic system disorders 16.7% (placebo 0%)
general disorders and administration 16.7% (placebo 40%)
nervous system disorders 16.7% (placebo 20%)
NCT03374241 · Phase 1
musculoskeletal and connective tissue 33.3% (placebo 0%)
eye disorders 16.7% (placebo 0%)
general disorders and administration 16.7% (placebo 40%)
NCT03374241 · Phase 1
gi disorders 57.1% (placebo 10%)
nervous system disorders 57.1% (placebo 20%)
general disorders and administration 28.6% (placebo 40%)
NCT03374241 · Phase 1
gi disorders 66.7% (placebo 10%)
infections and infestations 33.3% (placebo 0%)
nervous system disorders 33.3% (placebo 20%)
NCT03374241 · Phase 1
0.08 mg/kg
nausea 33.3% (placebo 5.9%)
bone contusion 11.1% (placebo 0%)
decreased appetite 11.1% (placebo 5.9%)
NCT03744182 · Phase 1 · registry result, not featured evidence
0.06 mg/kg
nausea 33.3% (placebo 5.9%)
decreased appetite 22.2% (placebo 5.9%)
chest pain 11.1% (placebo 5.9%)
NCT03744182 · Phase 1 · registry result, not featured evidence
0.04 mg/kg
glucose urine present 16.7% (placebo 5.9%)
nausea 16.7% (placebo 5.9%)
upper respiratory tract infection 16.7% (placebo 17.6%)
NCT03744182 · Phase 1 · registry result, not featured evidence
0.02 mg/kg
injection site erythema 20% (placebo 0%)
animal bite 10% (placebo 0%)
decreased appetite 10% (placebo 5.9%)
NCT03744182 · Phase 1 · registry result, not featured evidence
0.01 mg/kg
upper respiratory tract infection 44.4% (placebo 17.6%)
injection site erythema 11.1% (placebo 0%)
nausea 11.1% (placebo 5.9%)
NCT03744182 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Efocipegtrutide

BMI 35.74 vs 34.61 placebo kg @ 12wk0.08 mg/kg
absolute change · kg
NCT03744182 · Phase 1 · registry result, not featured evidence
show 4 more results
40.13 vs 34.61 placebo kg @ 12wk0.06 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
37.86 vs 34.61 placebo kg @ 12wk0.04 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
32.91 vs 34.61 placebo kg @ 12wk0.02 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence
35.46 vs 34.61 placebo kg @ 12wk0.01 mg/kg
NCT03744182 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Efocipegtrutide's landscape · HRS-4729's landscape